Commit Biologics secured €16 million in a seed funding led by Bioqube Ventures and Novo Holdings to accelerate the development of their immune system activation technology for cancer and autoimmune disease treatment.
Amount Raised
€16 Million
Round Type
Seed
AarhusBiotechnologyHealth CareTherapeuticsInvestors
Description
Commit Biologics, based in Aarhus, has secured €16 million in seed funding led by Bioqube Ventures and Novo Holdings. The company specializes in activating the complement system, a part of the immune system, to treat cancer and autoimmune diseases. The funding will be used to accelerate the development of their unique Bispecific Complement Engaging (BiCE™) platform, potentially revolutionizing cancer and autoimmune disease treatment.
Who to call at Commit Biologics, and when
A new round usually means Commit Biologics is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Commit Biologics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Commit Biologics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Commit Biologics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Commit Biologics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Commit Biologics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.